Biopharma manufacturing at inflection point amid rise of complex biologics, AI: report

Wednesday, May 13, 2026alundin@endeavorb2b.com (Andy Lundin)View original

Accenture found that 64% of 2024 drug-launch delays stemmed from CMC issues, highlighting mounting pressure on manufacturers to modernize operations.

Read the full article on the original site.